

Michigan **MEDICATION SECTION**

Atropine

Section 9-16 Revised Date:

Atropine

Protocols:

- 1. Bradycardia (Adult and Pediatric)
- 2. Poisoning
- 3. Nerve Agents/Organophosphate exposure

Indications:

- 1. Symptomatic bradycardia with a suspected vagal origin
- 2. Exposure to organophosphates or other nerve agents

Contraindications:

1. Known hypersensitivity (no absolute contraindications)

Dosing:

- 1. Symptomatic Bradycardia
 - a. Adult:
 - i. Administer 1 mg IV/IO every 3-5 minutes
 - ii. Max dose 3 mg



- **b.** Pediatric:
 - i. Given ONLY if primary AV block, or if bradycardia is unresponsive to oxygenation, ventilation and epinephrine.
 - ii. Administer 0.01-0.02 0.02 mg/kg IV/IO
 - iii. Minimum single dose 0.1 mg
 - iv. Maximum single dose 1 mg
 - v. Repeat prn in 5 minutes, maximum total dose 3 mg
- 2. Organophosphate/Nerve Agent Exposures
 - a. Adults
 - i. 2-6 mg IV/IM per Mark 1 Kit Dosing Directive (each kit contains 2 mg of atropine)
 - ii. If kit is not available administer 2-6 mg IV/IM as needed



- b. Pediatrics
 - i. Infant 0.05-0.1 mg/kg IM/IV/IO (0.2-1 mg), Pediatric Atropen or Vial
 - ii. Child 1-4 mg IM/IV/IO, Pediatric Atropen, Vial, or Mark 1

Expected Effects:

- 1. Increased heart rate
- 2. Dilated pupils

MCA Name: Genesee County

MCA Board Approval Date: February 3, 2022 MCA Implementation Date: August 1, 2022

Protocol Source/References: